This revenue range excludes revenue from Lucent Diagnostics testing, which is expected to be immaterial for 2024. The company also reaffirmed that it expects its research-use only business to achieve cash flow breakeven when it reaches revenue between $170M-$190M. The Company continues to expect GAAP gross margin percentage to be in the range of 57%-61%, and non-GAAP gross margin percentage to be in the range of 51%-55%. The company continues to anticipate 2024 cash usage to be approximately $30M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX: